Viagenpumatucel-L: Phase Ib/II data

Top-line data from 3 patients with advanced NSCLC previously treated with >=1 prior therapy in the open-label, U.S. Phase Ib/II DURGA trial showed that once-weekly injections of 1x10 7 cells of HS-110...